The global Hepatitis A Vaccine Market Comprehensive Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments -By Product (Inactivated vaccine, Live Attenuated Vaccine), By Application (Government Institution, Private Sector, Others)
In 2024, the Hepatitis A Vaccine market is witnessing robust growth, driven by the rising demand for vaccines to prevent hepatitis A infections. Hepatitis A vaccines, essential for immunization programs, are used to protect individuals and communities from the highly contagious liver disease. The market benefits from advancements in vaccine development and production technologies, the growing trend of preventive healthcare, and the expansion of global vaccination programs. Additionally, the increasing awareness of the importance of vaccination for public health and disease prevention is contributing to market growth.
The market report analyses the leading companies in the industry including Changchun Institute of Biological Products Co., Ltd., Changsheng Biotechnology Co., Ltd., Convac Pty Ltd., GlaxoSmithKline plc, International Medicine Biotech Co., Ltd. (IMBCA), KM Biologics Co., Ltd., Merck & Co., Inc., Sanofi S.A., Sinovac Biotech Ltd., Zhejiang Pukang Biotech Co., Ltd., and Others.
The most prominent trend in the Hepatitis A Vaccine Market is the rising demand for preventive healthcare. As consumers and healthcare providers seek to prevent infectious diseases, vaccines, including the Hepatitis A vaccine, are gaining traction for their ability to provide long-term immunity. This trend is driven by the increasing awareness of the importance of vaccination and the desire for effective preventive measures against Hepatitis A.
The key driver of the Hepatitis A Vaccine Market is the increase in global travel and tourism. As more people travel to regions where Hepatitis A is prevalent, there is a higher demand for vaccinations that protect against this infectious disease. This driver is supported by the trend towards preventive healthcare and the recommendations from health authorities for travelers to receive the Hepatitis A vaccine, driving growth for this sector.
A significant opportunity in the Hepatitis A Vaccine Market lies in the expansion of immunization programs. By increasing vaccination coverage through public health initiatives and educational campaigns, companies can help reduce the incidence of Hepatitis A. Offering accessible and affordable vaccines can help expand market reach and drive growth in the preventive healthcare sector, ultimately improving public health outcomes.
Inactivated vaccines are the largest segment in the Hepatitis A Vaccine Market by product. This dominance is due to their well-established safety profile and widespread use in immunization programs globally. Inactivated hepatitis A vaccines are composed of virus particles that have been killed, ensuring they cannot cause the disease. These vaccines are highly effective in stimulating an immune response without the risk of infection. Their stability and ease of storage make them suitable for mass vaccination campaigns. Inactivated vaccines are preferred for use in children, the elderly, and individuals with compromised immune systems, further contributing to their widespread adoption. The consistent demand for inactivated hepatitis A vaccines in routine immunization schedules and travel vaccination requirements reinforces their position as the largest segment in the market.
The private sector is the fastest-growing segment in the Hepatitis A Vaccine Market by application, projected to see significant growth by 2032. This rapid growth is driven by increasing awareness and proactive healthcare measures among the population, leading to higher demand for vaccinations through private healthcare providers. The private sector includes clinics, hospitals, and private healthcare facilities that offer hepatitis A vaccination services. The rise in disposable income and improved access to healthcare services have enabled more individuals to seek vaccinations from private healthcare providers. Additionally, the convenience and shorter wait times associated with private healthcare facilities appeal to many consumers. Employers and educational institutions are also increasingly recognizing the importance of vaccination and are partnering with private healthcare providers to offer vaccination programs, further boosting this segment. As awareness about hepatitis A and its prevention continues to grow, the private sector is expected to experience robust growth in the coming years.
By Product
Inactivated vaccine
Live Attenuated Vaccine
By Application
Government Institution
Private Sector
Others
Countries Analyzed
North America (US, Canada, Mexico)
Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, South East Asia, Rest of Asia)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Changchun Institute of Biological Products Co., Ltd.
Changsheng Biotechnology Co., Ltd.
Convac Pty Ltd.
GlaxoSmithKline plc
International Medicine Biotech Co., Ltd. (IMBCA)
KM Biologics Co., Ltd.
Merck & Co., Inc.
Sanofi S.A.
Sinovac Biotech Ltd.
Zhejiang Pukang Biotech Co., Ltd.
*- List Not Exhaustive
Chapter 1. TABLE OF CONTENTS
Chapter 2. Introduction to Hepatitis A Vaccine Market
2.1. Market Overview
2.2. Key Statistics and Report Highlights
2.3. Scope of the Comprehensive Study
2.3.1. Market Definition
2.3.2 Countries and Regions Covered
2.3.3 Research Objective
2.3.4 Units, Currency, and Conversions
2.3.5 Industry Value Chain
2.4. Key Market Segments
2.5. Key Companies
2.6. Study Period
Chapter 3. Strategic Analysis Review
3.1. Hepatitis A Vaccine Pricing Analysis and Forecast
3.2. Porter’s Five Forces
3.3. Market Ecosystem
3.4. SWOT Analysis
3.5. Regulatory Scenario
3.3. Effects of Inflation, Russia-Ukraine War, moderating economic growth, and other macroeconomic factors
Chapter 4. Competitive Landscape
4.1. Market Share Analysis
4.1.1. Global Hepatitis A Vaccine Market Share by Company, 2023
4.1.2. Product Offerings of Leading Hepatitis A Vaccine Companies
4.2. Market Entropy
4.2.1. New Product Launches in the Industry
4.2.2. Mergers, Acquisitions, Joint ventures, and Partnerships
4.3. Key Strategies and Best Practices
Chapter 5. Global Market Projections: Best, Reference, and Low Case Scenarios
5.1. Growth Analysis- Case Scenario Definitions
5.2. Low Growth Case Scenario Forecasts
5.3. Reference Growth Case Scenario Forecasts
5.4. High Growth Case Scenario Forecasts
Chapter 6. Market Dynamics
6.1. Hepatitis A Vaccine Market Drivers
6.2. Hepatitis A Vaccine Market Challenges
6.6. Hepatitis A Vaccine Market Opportunities
6.4. Hepatitis A Vaccine Market Trends
Chapter 7. Global Hepatitis A Vaccine Market Outlook Trends
7.1. Global Hepatitis A Vaccine Revenue (USD Million) and CAGR (%) by Type (2021-2032)
7.2. Global Hepatitis A Vaccine Revenue (USD Million) and CAGR (%) by Application (2021-2032)
7.3. Global Hepatitis A Vaccine Revenue (USD Million) and CAGR (%) by Product (2021-2032)
By Product
Inactivated vaccine
Live Attenuated Vaccine
By Application
Government Institution
Private Sector
Others
Chapter 8. Global Hepatitis A Vaccine Regional Analysis and Outlook
8.1. Global Hepatitis A Vaccine Revenue (USD Million) By Regions (2021- 2032)
8.2. North America Hepatitis A Vaccine Revenue (USD Million) by Country (2021-2032)
8.2.1. United States Hepatitis A Vaccine Regional Analysis and Outlook
8.2.2. Canada Hepatitis A Vaccine Regional Analysis and Outlook
8.2.3. Mexico Hepatitis A Vaccine Regional Analysis and Outlook
8.3. Europe Hepatitis A Vaccine Revenue (USD Million), by Country (2021-2032)
8.3.1. Germany Hepatitis A Vaccine Regional Analysis and Outlook
8.3.2. France Hepatitis A Vaccine Regional Analysis and Outlook
8.3.3. United Kingdom Hepatitis A Vaccine Regional Analysis and Outlook
8.3.4. Spain Hepatitis A Vaccine Regional Analysis and Outlook
8.3.5. Italy Hepatitis A Vaccine Regional Analysis and Outlook
8.3.6. Russia Hepatitis A Vaccine Regional Analysis and Outlook
8.3.7. Rest of Europe Hepatitis A Vaccine Regional Analysis and Outlook
8.4. Asia Pacific Hepatitis A Vaccine Revenue (USD Million) by Country (2021-2032)
8.4.1. China Hepatitis A Vaccine Regional Analysis and Outlook
8.4.2. Japan Hepatitis A Vaccine Regional Analysis and Outlook
8.4.3. India Hepatitis A Vaccine Regional Analysis and Outlook
8.4.4. South Korea Hepatitis A Vaccine Regional Analysis and Outlook
8.4.5. Australia Hepatitis A Vaccine Regional Analysis and Outlook
8.4.6. South East Asia Hepatitis A Vaccine Regional Analysis and Outlook
8.4.7. Rest of Asia Pacific Hepatitis A Vaccine Regional Analysis and Outlook
8.5. South America Hepatitis A Vaccine Revenue (USD Million), by Country (2021-2032)
8.5.1. Brazil Hepatitis A Vaccine Regional Analysis and Outlook
8.5.2. Argentina Hepatitis A Vaccine Regional Analysis and Outlook
8.5.3. Rest of South America Hepatitis A Vaccine Regional Analysis and Outlook
8.6. Middle East and Africa Hepatitis A Vaccine Revenue (USD Million) by Country (2021-2032)
8.6.1. Middle East Hepatitis A Vaccine Regional Analysis and Outlook
8.6.2. Africa Hepatitis A Vaccine Regional Analysis and Outlook
Chapter 9. North America Hepatitis A Vaccine Analysis and Outlook
9.1. North America Hepatitis A Vaccine Revenue (USD Million) by Segments (2021-2032)
9.1.1. North America Hepatitis A Vaccine Revenue (USD Million) by Type (2021-2032)
9.1.2. North America Hepatitis A Vaccine Revenue (USD Million) by Application (2021-2032)
9.1.3. North America Hepatitis A Vaccine Revenue (USD Million) by Product (2021-2032)
By Product
Inactivated vaccine
Live Attenuated Vaccine
By Application
Government Institution
Private Sector
Others
Chapter 10. Europe Hepatitis A Vaccine Analysis and Outlook
10.1. Europe Hepatitis A Vaccine Revenue (USD Million), by Segments (USD Million) (2021-2032)
10.1.1. Europe Hepatitis A Vaccine Revenue (USD Million) by Type (2021-2032)
10.1.2. Europe Hepatitis A Vaccine Revenue (USD Million) by Application (2021-2032)
10.1.3. Europe Hepatitis A Vaccine Revenue (USD Million) by Product (2021-2032)
By Product
Inactivated vaccine
Live Attenuated Vaccine
By Application
Government Institution
Private Sector
Others
Chapter 11. Asia Pacific Hepatitis A Vaccine Analysis and Outlook
11.1. Asia Pacific Hepatitis A Vaccine Revenue (USD Million), and Revenue (USD Million) by Segments (2021-2032)
11.1.1. Asia Pacific Hepatitis A Vaccine Revenue (USD Million) by Type (2021-2032)
11.1.2. Asia Pacific Hepatitis A Vaccine Revenue (USD Million) by Application (2021-2032)
11.1.3. Asia Pacific Hepatitis A Vaccine Revenue (USD Million) by Product (2021-2032)
By Product
Inactivated vaccine
Live Attenuated Vaccine
By Application
Government Institution
Private Sector
Others
Chapter 12. South America Hepatitis A Vaccine Analysis and Outlook
12.1. South America Hepatitis A Vaccine Revenue (USD Million), by Segments (2021-2032)
12.1.1. South America Hepatitis A Vaccine Revenue (USD Million) by Type (2021-2032)
12.1.2. South America Hepatitis A Vaccine Revenue (USD Million) by Application (2021-2032)
12.1.3. South America Hepatitis A Vaccine Revenue (USD Million) by Product (2021-2032)
By Product
Inactivated vaccine
Live Attenuated Vaccine
By Application
Government Institution
Private Sector
Others
Chapter 13. Middle East and Africa Hepatitis A Vaccine Analysis and Outlook
13.1. Middle East and Africa Hepatitis A Vaccine Revenue (USD Million), by Segments (2021-2032)
13.1.1. Middle East and Africa Hepatitis A Vaccine Revenue (USD Million) by Type (2021-2032)
13.1.2. Middle East and Africa Hepatitis A Vaccine Revenue (USD Million) by Application (2021-2032)
13.1.3. Middle East and Africa Hepatitis A Vaccine Revenue (USD Million) by Product (2021-2032)
By Product
Inactivated vaccine
Live Attenuated Vaccine
By Application
Government Institution
Private Sector
Others
Chapter 14. Hepatitis A Vaccine Company Profiles
14.1 Business Overview
14.2 Product Profiles
14.3 SWOT Profiles
14.5 Recent Developments
14.6 Financial Profile
List of Companies
Changchun Institute of Biological Products Co., Ltd.
Changsheng Biotechnology Co., Ltd.
Convac Pty Ltd.
GlaxoSmithKline plc
International Medicine Biotech Co., Ltd. (IMBCA)
KM Biologics Co., Ltd.
Merck & Co., Inc.
Sanofi S.A.
Sinovac Biotech Ltd.
Zhejiang Pukang Biotech Co., Ltd.
15. Methodology and Data Sources
15.1 Customization Offerings
15.2 Subscription Services
15.3 Related Reports
15.4 Publisher Expertise
LIST OF TABLES
Table 1 Market Segmentation Analysis
Table 2 Global Hepatitis A Vaccine Market Share of Leading Companies, 2023
Table 3 Product Offerings of Leading Companies
Table 4 Low Growth Scenario Forecasts
Table 5 Reference Case Growth Scenario
Table 6 High Growth Case Scenario
Table 7 Global Hepatitis A Vaccine Revenue (USD Million) And CAGR (%) By Type (2021-2032)
Table 8 Global Hepatitis A Vaccine Revenue (USD Million) And CAGR (%) By Application (2021-2032)
Table 9 Global Hepatitis A Vaccine Revenue (USD Million) And CAGR (%) By Product (2021-2032)
Table 10 Global Hepatitis A Vaccine Market Revenue (USD Million) By Regions (2021-2032)
Table 11 Global Hepatitis A Vaccine Market Share (%) By Regions (2021-2032)
Table 12 North America Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Table 13 Europe Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Table 14 Asia Pacific Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Table 15 South America Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Table 16 Middle East and Africa Hepatitis A Vaccine Revenue (USD Million) By Region (2021-2032)
Table 17 North America Hepatitis A Vaccine Revenue (USD Million) By Type (2021-2032)
Table 18 North America Hepatitis A Vaccine Revenue (USD Million) By Application (2021-2032)
Table 19 North America Hepatitis A Vaccine Revenue (USD Million) By Product (2021-2032)
Table 20 Europe Hepatitis A Vaccine Revenue (USD Million) By Type (2021-2032)
Table 21 Europe Hepatitis A Vaccine Revenue (USD Million) By Application (2021-2032)
Table 22 Europe Hepatitis A Vaccine Revenue (USD Million) By Product (2021-2032)
Table 23 Asia Pacific Hepatitis A Vaccine Revenue (USD Million) By Type (2021-2032)
Table 24 Asia Pacific Hepatitis A Vaccine Revenue (USD Million) By Application (2021-2032)
Table 25 Asia Pacific Hepatitis A Vaccine Revenue (USD Million) By Product (2021-2032)
Table 26 South America Hepatitis A Vaccine Revenue (USD Million) By Type (2021-2032)
Table 27 South America Hepatitis A Vaccine Revenue (USD Million) By Application (2021-2032)
Table 28 South America Hepatitis A Vaccine Revenue (USD Million) By Product (2021-2032)
Table 29 Middle East and Africa Hepatitis A Vaccine Revenue (USD Million) By Type (2021-2032)
Table 30 Middle East and Africa Hepatitis A Vaccine Revenue (USD Million) By Application (2021-2032)
Table 31 Middle East and Africa Hepatitis A Vaccine Revenue (USD Million) By Product (2021-2032)
LIST OF FIGURES
Figure 1. Market Scope
Figure 2. Pricing Forecasts Per Unit, 2023- 2032
Figure 3. Porter’s Five Forces
Figure 4. Global Hepatitis A Vaccine Market Revenue (USD Million) By Regions (2021-2032)
Figure 5. Global Hepatitis A Vaccine Market Share (%) By Regions (2023)
Figure 6. North America Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 7. United States Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 8. Canada Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 9. Mexico Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 10. Europe Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 11. Germany Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 12. France Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 13. United Kingdom Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 14. Spain Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 15. Italy Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 16. Russia Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 17. Rest of Europe Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 11. Asia Pacific Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 12. China Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 13. Japan Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 14. India Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 15. South Korea Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 16. Australia Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 17. South East Asia Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 18. South America Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 19. Brazil Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 20. Argentina Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 21. Rest of Asia Pacific Hepatitis A Vaccine Revenue (USD Million) By Country (2021-2032)
Figure 22. Middle East and Africa Hepatitis A Vaccine Revenue (USD Million) By Region (2021-2032)
Figure 23. Saudi Arabia Hepatitis A Vaccine Revenue (USD Million) By Region (2021-2032)
Figure 24. The UAE Hepatitis A Vaccine Revenue (USD Million) By Region (2021-2032)
Figure 25. Rest of Middle East Hepatitis A Vaccine Revenue (USD Million) By Region (2021-2032)
Figure 26. South Africa Hepatitis A Vaccine Revenue (USD Million) By Region (2021-2032)
Figure 27. Africa Hepatitis A Vaccine Revenue (USD Million) By Region (2021-2032)
Figure 28. North America Hepatitis A Vaccine Revenue (USD Million) By Type (2021-2032)
Figure 29. North America Hepatitis A Vaccine Revenue (USD Million) By Application (2021-2032)
Figure 30. North America Hepatitis A Vaccine Revenue (USD Million) By Product (2021-2032)
Figure 31. Europe Hepatitis A Vaccine Revenue (USD Million) By Type (2021-2032)
Figure 32. Europe Hepatitis A Vaccine Revenue (USD Million) By Application (2021-2032)
Figure 33. Europe Hepatitis A Vaccine Revenue (USD Million) By Product (2021-2032)
Figure 34. Asia Pacific Hepatitis A Vaccine Revenue (USD Million) By Type (2021-2032)
Figure 35. Asia Pacific Hepatitis A Vaccine Revenue (USD Million) By Application (2021-2032)
Figure 36. Asia Pacific Hepatitis A Vaccine Revenue (USD Million) By Product (2021-2032)
Figure 37. South America Hepatitis A Vaccine Revenue (USD Million) By Type (2021-2032)
Figure 38. South America Hepatitis A Vaccine Revenue (USD Million) By Application (2021-2032)
Figure 39. South America Hepatitis A Vaccine Revenue (USD Million) By Product (2021-2032)
Figure 40. Middle East and Africa Hepatitis A Vaccine Revenue (USD Million) By Type (2021-2032)
Figure 41. Middle East and Africa Hepatitis A Vaccine Revenue (USD Million) By Application (2021-2032)
Figure 42. Middle East and Africa Hepatitis A Vaccine Revenue (USD Million) By Product (2021-2032)
By Product
Inactivated vaccine
Live Attenuated Vaccine
By Application
Government Institution
Private Sector
Others
Countries Analyzed
North America (US, Canada, Mexico)
Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, South East Asia, Rest of Asia)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Global Hepatitis A Vaccine Market Size is valued at $XX Million in 2024 and is forecast to register a growth rate (CAGR) of 3.2% to reach $XX Million by 2032.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Changchun Institute of Biological Products Co., Ltd., Changsheng Biotechnology Co., Ltd., Convac Pty Ltd., GlaxoSmithKline plc, International Medicine Biotech Co., Ltd. (IMBCA), KM Biologics Co., Ltd., Merck & Co., Inc., Sanofi S.A., Sinovac Biotech Ltd., Zhejiang Pukang Biotech Co., Ltd.
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2032; Currency: Revenue (USD); Volume